Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 11 (RPL23AP11)
- Target
- RPL23AP11
- Molecular classification
- Pseudogene (non-coding DNA that resembles a protein-coding gene but is generally transcriptionally inactive and nonfunctional)
01
Overview
Ribosomal protein L23a pseudogene 11 (RPL23AP11) is a non-functional DNA sequence in the human genome that resembles the ribosomal protein L23a gene, but it does not encode a functional protein and is classified as a pseudogene. Pseudogenes arise from duplication or retrotransposition events and often accumulate mutations that render them incapable of producing active proteins. While some pseudogenes can affect expression of homologous genes through gene conversion or regulatory effects, there is no evidence that RPL23AP11 has such a biological role. RPL23AP11 is not recognized as a therapeutic target, biomarker, or druggable receptor. It may sometimes be confused with other members of the ribosomal protein L23a pseudogene family that have been considered for research purposes in disease association, but RPL23AP11 itself is not associated with any disease or therapy.
- Other names
- RPL23A_29_1408RPL23AP11Ribosomal protein L23a pseudogene 11
02
Mechanism of action
Null. No mechanism of action for drugs, as this is not a druggable target
03
Biological functions
Other (Pseudogenes typically do not have a biological function; however, some pseudogenes may influence expression of related protein-coding genes through regulatory mechanisms, but there is no evidence presented for a functional biological role of RPL23AP11)
04
Disease associations
Other (No direct disease association; no role in disease/therapeutics is presented for RPL23AP11. By analogy, other ribosomal protein L23a pseudogenes such as RPL23AP53 have been explored for prognostic utility in cancer, but not RPL23AP11)
05
Safety considerations
None. As a pseudogene, there are no reported safety concerns relating to therapeutic intervention
06
Interacting drugs
None. No drugs are reported to directly interact with RPL23AP11
07
Biomarkers
None. RPL23AP11 is not currently used as a clinical biomarker. Other pseudogenes, such as RPL23AP53, have been investigated as prognostic markers, but this does not extend to RPL23AP11
Beyond the preview
Go deeper on Ribosomal protein L23a pseudogene 11 (RPL23AP11).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 11 (RPL23AP11).